

Supplementary Table 2

ALF n = 30	Adrenal insufficiency (AI)		No adrenal insufficiency (No AI)	
	All (n)	thereof with GC treatment (n (%))	All (n)	thereof with GC treatment (n (%))
Number of patients				
BL <275 nmol/L (CLIA)	5	2 (40)	24	9 (37.5)
BL <414 nmol/L (CLIA)	15	3 (20)	14	8 (57.1)
peak cortisol <550 nmol/L (CLIA)	2	0 (0)	26	11 (42.3)
Δ <250 nmol/L + BL >275 nmol/L (CLIA)	5	3 (60)	23	8 (34.8)
Δ <250 nmol/L + BL >414 nmol/L (CLIA)	2	2 (100)	26	9 (34.6)
BL <275 nmol/L (LC-MS)	10	3 (30)	9	4 (44.4)
BL < 414 nmol/L (LC-MS)	12	3 (25)	7	4 (57.2)

ACLF n = 34	Adrenal insufficiency (AI)		No adrenal insufficiency (No AI)	
	All (n)	thereof with GC treatment (n (%))	all	thereof with GC treatment (n (%))
Number of patients				
BL <275 nmol/L (CLIA)	5	1 (20)	28	13 (46.4)
BL <414 nmol/L (CLIA)	15	4 (26.7)	18	9 (50)
peak cortisol <550 nmol/L (CLIA)	7	3 (37.5)	26	11 (42.3)
Δ <250 nmol/L + BL >275 nmol/L (CLIA)	13	7 (53.8)	20	7 (35)
Δ <250 nmol/L + BL >414 nmol/L (CLIA)	6	3 (50)	28	10 (35.7)
BL <275 nmol/L (LC-MS)	11	1 (9.1)	18	9 (50)
BL < 414 nmol/L (LC-MS)	19	4 (21.1)	10	7 (70)

Stable cirrhosis n = 8	Adrenal insufficiency (AI)		No adrenal insufficiency (No AI)	
	All (n)	thereof with GC treatment (n (%))	all	thereof with GC treatment (n (%))
Number of patients				
BL <275 nmol/L (CLIA)	1	0 (0)	7	0 (0)
BL <414 nmol/L (CLIA)	6	0 (0)	2	0 (0)
peak cortisol <550 nmol/L (CLIA)	1	0 (0)	7	0 (0)
Δ <250 nmol/L + BL >275 nmol/L (CLIA)	2	0 (0)	6	0 (0)
Δ <250 nmol/L + BL >414 nmol/L (CLIA)	1	0 (0)	7	0 (0)
BL <275 nmol/L (LC-MS)	4	0 (0)	2	0 (0)
BL < 414 nmol/L (LC-MS)	4	0 (0)	2	0 (0)